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Viral infection such as hepatitis C or B virus is the major cause for
chronic hepatitis or liver cirrhosis, which enhances the risk of
developing hepatocellular carcinomas (Dusheiko, 1990; Matsuda
et al, 1995). It has been demonstrated that apoptotic cell death of
liver cells occurs in acute or chronic hepatitis and that Fas-medi-
ated liver cell apoptosis accounts for T-cell-mediated cytotoxicity
against liver cells (Hiramatsu et al, 1994; Mita et al, 1994). Up-
regulation of Fas occurs in acute or chronic liver diseases due to
viral infections (Okazaki et al, 1996; Ando et al, 1997; Saile et al,
1997). It has been suggested that apoptotic cell death induced by
Fas/Fas ligand system plays a critical role in the clearance of virus-
infected liver cells (Mochizuki et al, 1996; Hayashi and Mita,
1997). Thus, apoptotic cell death of virus-infected hepatocytes is
an integral component of the disease process in chronic hepatitis
or liver cirrhosis (Jiang et al, 1997).
In animal models, sustained or repeated liver cell damage
induced by frequent partial hepatectomy or carbon tetrachloride
administration is known to stimulate cell proliferation and
influence the promotion phase of hepatocarcinogenesis, thereby
increasing the number of preneoplastic lesions and tumours
(Pound and McGuire, 1978a; Lindroos et al, 1991). It has been
hypothesized that Fas-mediated apoptosis, induced by Fas ligand
expressed by cytotoxic T-cell in chronic hepatitis or liver cirrhosis,
is critical step in hepatocyte proliferation and promotion of hepa-
tocarcinogenesis. Recently, it has been reported that intraperi-
toneal administration of monoclonal anti-Fas antibody (which
possesses cytolytic activity against cells expressing mouse Fas
antigen) induces apoptotic liver cell death (Ogasawara et al, 1993;
Nishimura et al, 1997).
In the present study, we examined the in vivo effects of Fas-
mediated apoptosis, induced by intraperitoneal (i.p.) administra-
tion of a monoclonal antibody against mouse Fas antigen, on
DEN-induced hepatocarcinogenesis of C3H/HeJ mouse hepato-
cytes. We also evaluated the effect of this antibody on acute liver
cell damage, using the terminal dUTP-biotin nick end labelling
(TUNEL) method (Gavrieli et al, 1992).
MATERIALS AND METHODS
Mice
C3H/HeJ mice were purchased from Japan SLC Inc. (Hamamatsu,
Japan). Only male C3H/HeJ mice were used in this study. The
animals were housed in plastic cages under controlled conditions
of 23 ± 2°C, 50 ± 10% humidity and a 12 h light/dark cycle. They
were fed commercial pellet CE-2 diet (Nippon Clea Co., Tokyo,
Japan). The animal studies were carried out with the approval of
our institutional committee of the care and use of laboratory
animals.
Evaluation of acute liver damage induced by anti-Fas
antibody
The acute liver damage 12 h after i.p. administration of Jo2
antibody at high (5 mg animal–1) or low (2 mg animal–1) dose was
assessed histologically using haematoxylin and eosin (H & E)
staining and TUNEL methods. The rationale for using these doses
was based on preliminary studies showing that administration of
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Correspondence to: A HaraJo2 at 10 and 100 mg animal–1 in C3H/HeJ mice resulted in 50%
and 0% survival respectively, and that 5 and 2 mg animal–1 Jo2
antibody treatment induced gross or scattered liver cell damage
respectively. Male C3H/HeJ mice at 5 weeks of age received a
single i.p. administration of Jo2 antibody at a dose of 5 or 2 mg
animal–1 in physiological saline. The mice were sacrificed 12 h
after the treatment, and the livers were removed and prepared for a
histological examination. Five animals were used for each dose of
the antibody to analyse liver damage. Five animals were also used
as negative controls.
In situ labelling of DNA fragmentation of acute liver
damage
The TUNEL assay was performed using some modification of the
method of Gavrieli et al (Gavrieli et al, 1992; Hara et al, 1995a;
1995b). After incubation with 20 mg ml–1 proteinase K (Sigma),
the liver sections were immersed in TDT buffer (30 mM Trizma
base, pH 7.2, 140 mM sodium cacodylate, 1 mM cobalt chloride).
TDT (Boehringer Mannheim GmbH, Mannheim, Germany) and
biotinylated dUTP (Boehringer Mannheim GmbH) were diluted in
TDT buffer at concentrations of 0.15 e.u. ml–1 and 0.8 nmol respec-
tively. The solution was placed on the sections, and then incubated
at 37°C for 60 min. The sections were covered with streptavidin
peroxidase (Dako Co., Carpinteria, CA, USA), and stained with
3,3¢-diaminobenzidine as a substrate for the peroxidase. Finally,
counter staining was done using Mayer’s haematoxylin. The
percentage of TUNEL-positive cells in liver was determined by
measuring the number of liver cells possessing dark-brown nuclei,
as a proportion of the entire cell number of liver parenchymal
cells.
Fas-mediated apoptosis on DEN-induced
hepatocarcinogenesis
At 14 days of age, a total of 125 male C3H/HeJ mice (group 1–5)
received i.p. injection of DEN (Sigma Chemical Co., St Louis,
MO, USA) dissolved in physiological saline at a dose of 10 mg g–1
body weight. All mice were weaned 3 weeks after birth. Control
mice (group 6–8) at the same age received i.p. injection of physio-
logical saline. At 5 weeks of age, groups 1, 2 and 6 were treated
i.p. with hamster monoclonal antibody (Jo2 antibody) against
mouse Fas antigen (Pharmingen, San Diego, CA, USA) at a dose
of 5 mg animal–1 in physiological saline. Group 1 (n = 24) received
a single administration of this antibody, whereas groups 2 (n = 22)
and 6 (n = 20) received five i.p. injections at every 3 weeks.
Groups 3, 4 and 7 were treated i.p. with Jo2 antibody (2 mg
animal–1 in physiological saline). Group 3 (n = 24) received single
administration of the antibody, whereas groups 4 (n = 25) and
7 (n = 21) received five i.p. injections every 3 weeks. Group 5
(n = 25) received only i.p. injection of DEN, and group 8 (n = 10)
was non-treated control. The survival rate of mice receiving one
dose of 5 mg animal–1 of Jo2 antibody was 90%, while 100% of
animals survived the 2 mg animal–1 dose. The mice that did not
survive the antibody treatment died within 12 h after the injection.
Histologically, acidophilic cytoplasm, pyknotic cell nuclei and
severe haemorrhage were present in the livers of all the mice that
died from injection of 5 mg animal–1 of Jo2 antibody. In Groups 2
and 6, no mice died following four injections of 5 mg animal–1 of
Jo2 antibody.
Studies of liver tumours
At 40 weeks of age, all mice were killed by ether anaesthesia.
Livers were excised, weighed and examined for the presence of
visible lesions. The number and location of the lesions were
recorded. Livers were sliced at 2-mm intervals, following fixation
in 10% phosphate-buffered formalin for 48 h. The number of
grossly visible lesions were reconfirmed in the sliced livers. The
formalin-fixed livers were dehydrated and embedded in paraffin
for histological studies.
Histological analysis
From each paraffin-embedded specimen, 3-mm-thick sections
were cut. Deparaffinized sections were stained with H&E. The
incidences of hepatocellular carcinomas and adenomas were histo-
logically discriminated and quantified by two pathologists using
criteria defined previously (Frith and Ward, 1979; Lipsky et al,
1981; Klaunig et al, 1987). Furthermore, adenomas were classified
into two subgroups; small-sized adenomas which are less than
5 mm in diameter and large-sized adenomas that are more than
5 mm in diameter. Differences of liver tumour incidences among
the groups were analysed statistically by Student’s t-test.
RESULTS
Acute liver damage induced by Jo2
Histologically, livers of mice 12 h after exposure to 5 mg animal–1
Jo2 antibody (high dose), showed many areas of focal haemor-
rhage, and abundant hepatocytes with eosinophilic swollen
cytoplasm and pyknotic nuclei. Only hepatocytes localized in the
centrolobular regions survived. In TUNEL staining, positive
reaction was evident in most hepatocytes associated with apoptotic
cell nuclei, although a few non-apoptotic cells remained in the
centrolobular regions. In contrast, acidophilic cells with pyknotic
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Figure 1 Mean apoptotic rates of Jo2-induced acute liver damage 12 h
after i.p. administration of Jo2 antibody at the doses of 0, 2 and 5 mg
animal–1. Apoptotic rate was determined by measuring the number of
TUNEL-positive liver cells as a proportion of the entire cell number of liver
parenchymal cellsnuclei were found scattered throughout the liver of mice treated
with 2 mg animal–1 Jo2 antibody (low dose). In addition, no
specific zonal distribution of these cells was noted. TUNEL
staining revealed that apoptotic cells were distributed sparsely in
the liver tissue. Control mice without Jo2 treatment had neither
damaged hepatocytes nor apoptotic cells in the liver. The mean
number of apoptotic cells per 500 hepatocytes of mice at the high
dose and low dose of Jo2, and that of negative controls were
84.4  ± 9.3, 10.6 ± 3.8 and 0 ± 0 respectively (Figure 1).
Development of liver tumours
As summarized in Table 1, the liver tumours were only detected in
the groups treated with DEN (groups 1–5). All the neoplasms were
histologically determined as having a hepatocellular origin. Jo2
antibody administered five times at high (group 6) or low (group
7) dose, without DEN administration, induced no liver tumours.
Effects of Jo2 at high dose on DEN-induced
hepatocarcinogenesis
Total number of liver tumours of mice receiving single (group 1)
or multiple (group 2) treatments of high dose Jo2 antibody was
significantly lower (P < 0.01 and P < 0.001 respectively) than that
of mice treated with DEN alone (group 5). Importantly, the
number of adenomas < 5 mm in diameter in both groups 1 and 2
were less than that of group 5 (P < 0.001), indicating that high
dose Jo2 antibody markedly reduced the DEN-induced liver
tumours, irrespective of the frequency of the administration and
that the suppressive effect was apparent in small-sized adenomas.
Effects of Jo2 at low dose on DEN-induced
hepatocarcinogenesis
In contrast to high dose Jo2, the effect of low dose antibody given
5 times (group 4) significantly increased both the number of
adenomas > 5 mm in diameter (P < 0.05), and also carcinomas
(P < 0.02). Treatment of Jo2 had no effect on the number of
adenomas < 5 mm in diameter (group 5). The single administration
of Jo2 (group 3), however, showed no effect on the number of
small- and large-sized adenomas and carcinomas. These findings
suggest that frequent administration of low dose of Jo2 increased
the DEN-induced liver tumours and that the effect of Jo2 was
apparent in large-sized adenomas and carcinomas.
DISCUSSION
Fas, which is a member of the tumour necrosis factor/nerve growth
factor receptor family (Smith et al, 1994), is expressed in varied
types of tissues, particularly in liver (Watanabe-Fukunaga et al,
1992; Leithauser et al, 1993). Fas-mediated apoptosis may serve to
eliminate liver cells in which hepatocarcinogenesis has been
initiated by carcinogens. However, carcinogen-exposed liver cells
which survive Fas-mediated programmed cell death may acquire a
potential for neoplastic transformation due to a regenerative
response of the remaining liver tissue. Hence, it could be argued
that differences in sensitivity of initiated and non-initiated liver
cells to Fas-ligand results in the cells developing different
potentials for neoplastic transformation. In fact, the differential
sensitivity to Fas-mediated apoptosis has been demonstrated for
both carcinoma cells and normal liver cells (Higaki et al, 1996).
In this study, dose-related liver cell damage by Jo2 antibody in
male C3H/HeJ mice was evaluated. High dose of Jo2 antibody
generated hepatocytes with typical characteristics of apoptosis,
namely eosinophilic swollen cytoplasm, pyknotic nuclei and
apoptotic bodies. These morphological features appeared to be
coincident with those of the human fulminant hepatitis
(Ogasawara et al, 1993). In contrast, low dose of Jo2 antibody
produced acidophilic cells with pyknotic nuclei throughout the
liver tissue without specific zonal distribution. Such finding is
similar to that of human chronic hepatitis (Jiang et al, 1997). The
apoptotic liver cell death was confirmed by TUNEL staining.
Interestingly, high dose of Jo2 antibody suppressed DEN-
induced liver tumours independent of the frequency (single or
5 times) of administration. The suppressive effect of Jo2 occurred
primarily in small-sized adenomas, and while the numbers of
large-sized adenomas and carcinomas were also decreased by this
treatment the effects did not reach statistical significance. Thus,
while gross liver damage by Fas-mediated apoptosis reduced the
number of liver tumours, the process of the hepatocarcinogenesis
itself may not be markedly affected. On the other hand, low dose
of Jo2 antibody increased the number of large-sized adenomas and
carcinomas, and the effect was particularly apparent with multiple
administration of the antibody. This suggests that frequent or
chronic induction of sparsely-distributed apoptotic cell death in
liver provokes the development of large-sized adenomas and
carcinomas, or the malignant progression of liver neoplasms.
Difference of the sensitivity to induction of Fas-mediated
apoptosis between normal hepatocytes and neoplastic cells or
virus-infected cells has previously been reported. It is known that
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Table 1 Tumour induction in DEN-initiated mice treated with Jo2 anti-Fas antibody
Group DEN Dose of No of times No. Mean no. Mean no. of Mean no. of Mean no. of
Jo2 of Jo2 of of liver tumours adenomas (< 5 mm) adenomas (> 5 mm) carcinomas
(mg animal–1) treatment mice per mouse per mouse per mouse per mouse
1 + 5 1 24 6.0 ± 5.4a,b 5.0 ± 3.7c 1.0 ± 2.3 0.1 ± 0.3
2 + 5 5 22 5.6 ± 4.5c 4.6 ± 2.6c 1.0 ± 2.3 0.0 ± 0.0
3 + 2 1 24 10.2 ± 7.9 7.4 ± 5.9 2.8 ± 3.3 0.1 ± 0.2
4 + 2 5 25 14.6 ± 11.0 9.7 ± 5.2 4.0 ± 5.5d 0.9 ± 1.5e
5 + – – 25 10.9 ± 5.0 9.2 ± 3.8 1.6 ± 2.4 0.1 ± 0.3
6 – 5 5 20 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
7 – 2 5 21 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
8 – – – 10 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
a Values are mean ± s.d. b,c,d,e Significantly different from mice treated with DEN alone by Student’s t-test (bP < 0.01, cP < 0.001, dP < 0.05, eP < 0.02).some human neoplastic liver cells show resistance to Fas-mediated
apoptosis in vitro (Natoli et al, 1995). SV40 T-antigen contributing
to viral pathogenesis is also known to protect the infected liver
cells against the host apoptotic defence mechanism (Rouquet et al,
1995). Furthermore, Higaki et al (1996) demonstrated a relation-
ship between Fas expression and apoptotic cell numbers in human
hepatocellular carcinomas and related liver tissues. They estab-
lished that apoptotic cell counts were significantly higher in
Fas-expressing tissues than in Fas-negative tissues, and that
hepatocellular carcinoma tissues expressed Fas less frequently and
more weakly than noncancerous tissues. These findings imply that
neoplastic liver cells may be less sensitive to Fas-mediated
apoptosis than non-neoplastic liver cells. In the present study, high
dose of Jo2 antibody suppressed occurrence of liver tumours,
whereas low dose promoted the tumorigenesis. Our data suggest
that high dose of Jo2 antibody induces apoptosis in both non-initi-
ated and initiated liver cells, but low dose of Jo2 antibody
produces apoptosis in only non-initiated liver cells, which makes
initiated cells survive and regenerate after the frequent exposure to
low dose Jo2 antibody.
Tumour-suppressing effects are recognized not only in Fas-
mediated apoptosis but apoptosis induced by chemical agents. It is
hypothesized that lead nitrate decreases the number of hyper-
plastic lesions in DEN-treated rats by inducing apoptotic cell death
of initiated hepatocytes (Columbano et al, 1991). Contrary to
apoptosis-related suppressing effects, it is known that stimulation
of cell proliferation greatly influences the promotion phase of
carcinogenesis, and then increases the number of preneoplastic
lesions and tumours (Pound and McGuire, 1978a, 1978b; Dragani
et al, 1986; Lindroos et al, 1991). Liver is essentially a quiescent
organ with respect to hepatocyte proliferation. Liver cell prolifera-
tion is usually stimulated by partial hepatectomy or carbon tetra-
chloride-induced acute liver damage in rodent models of
hepatocarcinogenesis (Pound and McGuire, 1978a; Lindroos et al,
1991). Regenerative growth following liver injury has been shown
to promote hepatocarcinogenesis in mice (Pound and McGuire,
1978b; Dragani et al, 1986). Our results suggests that low dose Jo2
antibody induces the regenerative growth following apoptotic liver
cell injury and then promotes DEN-induced hepatocarcinogenesis.
In conclusion, our results suggest that high dose of anti-Fas anti-
body induces gross liver cell apoptosis and plays an important role
in the clearance of DEN-initiated liver cells, and that frequent
treatment of low dose of anti-Fas antibody generates scattered
liver cell apoptosis and exert a promoting effect on the DEN-
induced hepatocarcinogenesis. Accordingly, Fas-mediated liver
cell apoptosis plays a biphasic effect on hepatocarcinogenesis.
Further studies are warranted to elucidate the difference of sensi-
tivity of initiated and non-initiated liver cells to Fas/Fas ligand
system.
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